Please use this identifier to cite or link to this item:
http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5094Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Bystricky B | - |
| dc.creator | Okines AFC | - |
| dc.creator | Cunningham D | - |
| dc.date | 2011 | - |
| dc.date.accessioned | 2013-05-30T12:15:16Z | - |
| dc.date.available | 2013-05-30T12:15:16Z | - |
| dc.date.issued | 2013-05-30 | - |
| dc.identifier | http://www.dovepress.com/targeting-her-2-in-gastric-cancer-ndash-incorporation-of-trastuzumab-i-a7890 | - |
| dc.identifier | http://www.doaj.org/doaj?func=openurl&genre=article&issn=11799919&date=2011&volume=2011&issue=default&spage=41 | - |
| dc.identifier.uri | http://koha.mediu.edu.my:8181/jspui/handle/123456789/5094 | - |
| dc.description | Branislav Bystricky, Alicia FC Okines, David CunninghamRoyal Marsden Hospital NHS Trust, Sutton and London, UKAbstract: Gastric cancer is the fourth most common malignancy and second leading cause of cancer death world-wide, and is therefore a significant global health problem. Radical surgery with a D2 lymph node dissection is an accepted standard approach, and is a key component of multimodality therapy. Perioperative chemotherapy significantly improves 5-year overall survival compared with surgery alone. A significant improvement in overall survival has also been demonstrated with postoperative 5-fluorouracil-based chemoradiotherapy and adjuvant oral S-1 chemotherapy; approaches commonly used widely in North America and Japan, respectively. Approximately 10% to 20% of gastric cancers and 20% to 30% of esophago-gastric junction cancers are HER-2 positive. The effect of HER-2 overexpression and HER-2 gene amplification on gastric cancer prognosis remains unresolved. The results of the first randomized phase III trial of trastuzumab, a monoclonal antibody directed at the HER-2 receptor, in patients with metastatic gastric cancer were reported recently. Response rate, median progression-free survival, and median overall survival were all significantly improved with the addition of trastuzumab to a cisplatin/fluoropyrimidine doublet. Evaluation of trastuzumab in HER-2 positive operable esophago-gastric cancer is now underway. Lapatinib, a small-molecule inhibitor targeting EGFR and HER-2 is well established in the treatment of trastuzumab-refractory HER-2 positive breast cancer and phase III trials in advanced esophago-gastric cancers are ongoing. Novel, small molecule pan-HER inhibitors have entered early phase evaluation and the antibody-drug conjugate, trastuzumab-DM1, and pertuzumab, a monoclonal antibody which prevents HER-2/HER-3 dimerization, are currently undergoing phase II/III evaluation in breast cancer. It is our hope that advances in the targeted treatment of HER-2 positive breast cancer will be replicated in HER-2 positive esophago-gastric cancers.Keywords: gastric cancer, adjuvant, perioperative, chemotherapy, trastuzumab, HER-2 | - |
| dc.language | eng | - |
| dc.publisher | Dove Press | - |
| dc.source | Gastrointestinal Cancer : Targets and Therapy | - |
| dc.title | Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease | - |
| Appears in Collections: | Health Sciences | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.